华东医药三款创新药进入国家医保/商保目录

Core Insights - The new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) and the Commercial Health Insurance Innovative Drug Catalog (2025) have been officially released, with significant inclusions for certain drugs [1] Group 1: Drug Catalog Updates - The drug "Dihydropyridine Linalool Ester Capsules" has been successfully included in the new drug catalog [1] - "Senapali Capsules" and "Zevokiorunsai Injection" (Sikaze®), both exclusively commercialized by East China Pharmaceutical, have also been added to the new drug catalog and the first commercial health insurance innovative drug catalog [1] - East China Pharmaceutical now has a total of three innovative drug products included in either the new drug catalog or the first commercial health insurance innovative drug catalog [1] Group 2: Implementation and Impact - The new catalog will be fully implemented starting January 1, 2026, allowing more ovarian cancer patients in China to access affordable treatment options [1]